Scientia CME: Turning the tide toward precision care for metastatic urothelial carcinoma

Cost: Free

View Offer chevron_right

Details

In this online, self-learning activity:

Urothelial carcinoma (UC) is a cancer affecting both the bladder and beyond, including tumors of the upper urinary tract and proximal urethra. Cancers of the urinary tract affect more than 1.6 million people worldwide and collectively are the 6th most common type of cancer in the US. UC itself accounts for over 84,000 new cases and 17,000 deaths each year. The five-year survival for noninvasive UC is 96%, but the five-year survival drops to eight percent for metastatic disease (mUC), suggesting there may be room for improvement in the management of the disease.

Topics Covered

Faculty introduction and disclosures

mUC introductory content 

  • Epidemiology: statistics by age & gender
  • Pathophysiology, updates on molecular targets
  • Prognostic factors: molecular, clinical

Treatment of mUC 

  • Goals of therapy
  • First-line therapy
    • Cisplatin-based chemotherapy, MVAC vs. GC
    • Cisplatin-ineligible patients
    • Carboplatin-based therapy
    • Non-platinum regimens: immunotherapy regimens
  • Maintenance therapy
  • Second-line and later-line therapies
    • Immunotherapy
    • FGFR-positive vs. -negative disease
    • Alternatives to targeted therapy
  • Trial vs. real-world data
  • Updates in investigational therapies
  • Supportive care
  • Treatment challenges
    • Importance of the multidisciplinary care team (MDT):
      • Recognition, management, and mitigation of treatment-related adverse events
      • Related patient education and patient-reported outcomes
    • Special populations: higher ECOG PS score, organ dysfunction, immune or autoimmune diseases, patients receiving steroid therapy
  • Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Summarize challenges related to the health burden and treatment of mUC.
  • Describe first-line, later-line, and investigational pharmacotherapies for and factors impacting therapeutic decision-making in mUC.
  • Develop a treatment plan for a patient with mUC.

Target Audience

HCPs including but not limited to: medical and genitourinary oncologists and urologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology and urology; and any other HCPs with an interest in or who clinically encounter patients with advanced UC.

Additional credit info

ACCME Activity #203259887

ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME-MOC_badge

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner’s responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.

Pharmacists

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours  of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-25-012-H01-P. This is an Application (A)-type activity. 

Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner’s responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Stay up-to-date

Receive special offers, keep up with MOC requirements and stay informed of the latest offerings in free online CME in your specialty.